

# 2018 – CHF 1236 million for startups





#### **Authors**




Stefan Kyora Editor in Chief at Startupticker.ch stefan.kyora@jnb.ch Tel. 041 226 20 80



Thomas Heimann Head of Research & Statistics at SECA thomas.heimann@seca.ch Tel. 079 709 02 96

#### At a glance

#### 30% growth



**Deep Tech Nation** 

### **Broad range of sectors**

Fintech, ICT, Biotech, Medtech, Healthcare IT, Cleantech

SEBA	ne think. change your perspective	W A Y R A Y	Therachon achieving potential	CHRONEXT
	SCANDIT			polaresmedical
<b>AMAL</b> Therapeutics	coople	CO CELLESTIA BIOTECH	🎌 MetrioPharm	NBE therapeutics
<b>G</b> oculis	🔎 abionic	VERITY <sup>™</sup> studios	STARMIND	KANDOU BUS

# 7 B2B ICT startups among Top 20 (2017: 3)



Investments by Google, Index, Alibaba, Sony et.

# Swiss investors involved in 9 Top 20 rounds (2017: 6)

Share of Top 20 rounds: 56% (2017: 73%)

# **International Comparison**

# On par with Sweden


#### Invested capital in Top 20 rounds by country, 2018 2550 UK CHFm 2290 Germany 13 rounds above CHF 1411 100 million in the UK France 1174 Israel 687 Switzerland 605 Sweden 449 Netherlands

**#SVCR19** 

3 largest rounds from


Germany

# High sector diversity in Sweden, CH and UK



# ICT sector with highest share of volume invested **Fintech** is leading sector in UK 6 Cleantech rounds among Top 20 in the Netherlands Life Sciences with 36% volume share in Sweden

### In search of the unicorns



#### A New Vintage Year (more than a dozen new funds)


Aravis	Aravis Growth I	Switzerland, opportunis- tically Europe	Creative and digital, life sciences, industrial high tech, special situations	Growth stage (minimum turnover CHF 5 million)	CHF 200 million
Alpana Ventures	Alpana Ventures Investments II	CH, Europe, USA	Digital technologies	Early stage	USD 50 million
Avaloq Ventures	n.a.	Global	Fintech	n.a.	n.a.
Bellevue Asset Management	BB Pureos Bioventures	n.a.	Biotech, drug develop- ment	n.a.	n.a.
BioMedPartners	BioMedInvest-III	DACH (Germany, Austria, Switzerland), France, Italy, Belgium, the Neth- erlands, Luxembourg	Biopharma / biotech, pharma (majority), medtech / devices, diagnostics	Late stage preclinical / early clinical; before / at CE	CHF 100 million
BlueOcean Ventures	BlueOcean Ventures (alias BlueOcean Ventures II)	Europe with special focus on Switzerland	Medtech and life sciences	Early stage (initial investment in seed or series A )	CHF 25 million
btov Partners	btov Industrial Technologies Fund	Europe (focus on DACH)	Industrial technologies	Early stage	EUR 100-125 million
Creathor Ventures	Creathor Ventures Technology Fund	DACH	loT, Industry 4.0, automation	Seed / pre-series A / series A	EUR 75-100 million
Creathor Ventures	Creathor Ventures Digital Healthcare Fund	DACH	loT, Industry 4.0, automation	Seed / pre-series A / series A	EUR 75-100 million
DeepTech Ventures	DeepTech Ventures I	Europe	Deep-tech (insurance, pharma, other sectors)	Pre-seed / seed	EUR 30-60 million
Endeavour Vision	Endeavour Medtech Growth II	Switzerland, EU and US	Medtech	Growth stage	USD 400 million
MTIP	MTIP Fund II	Primarily Europe	Digital health and medtech	Early revenues	n.a.
Nextech Invest	Nextech V Oncology	Global (US, EU)	Oncology	Focus on series B	CHF 240 million
Redalpine Venture Partners	Redalpine Capital IV	Europe (focus on DACH)	Tech, healthtech, deep-tech	Seed / early stage	Close at CHF 100 million
Spicehaus Partners	Spicehaus Swiss Venture Fund	Switzerland (80-100%), international (0-20%)	Technology	Seed / early stage	Minimum fund size CHF 20 million
Swisscanto Invest at Zürcher Kantonal- bank	Swisscanto Private Equity Switzerland Growth I	Switzerland, opportunis- tic in Germany, Austria, Scandinavia, Benelux	Technology (ICT, industry), healthtech	Late stage venture / growth capital	CHF 200 million
Swisscom (Schweiz)	Digital Transfor- mation Fund	CH, EU, US, Israel	ICT	Early-to-growth	CHF 150 million plus CHF 50 million allocated to Swisscom's balance sheet

\* Funds with direct investments only, advisor / manager domiciled in Switzerland, not exhaustive

#### **Sectors**

CHFm

# First time more ICT than Life Sciences



```
ICT - CHF 685 million
```

```
invested
```

ICT alone is twice as large


#### as biotech

55% of total investment

131 financing rounds (60% of

all rounds)

# Strongest increase in ICT and Fintech



ICT (and fintech): +124%

Largest ICT rounds: around

40% of total investments

Seven times more ICT money


than 5 years ago

```
Biotech -43%
```

Medtech +42%

#### Phases

# Growth at all stages




Seed: +333%, early: +62%, later rounds: +15% Share of seed and early: 34% Larger later stage ICT rounds (+126%)

Later stage Biotech (-63%)

#SVCR19

#### Phases


# Less dependent on larger rounds




#SVCR19 Amount known for 185 financing rounds (80% of total)

## **Phases / Sectors**

# Average per round remained at last years' level




Average per round - per sector (CHF m)



# Strongest increase in 10-20 million rounds

#### and high growth in number of rounds up to 2 million



Number of rounds up to CHF 10 m; n: 502

#SVCR19


+150%

2018

#### **Phases / Sector**

# 5-times more ICT rounds between 10-20 m

#### and 3-times more rounds up to CHF 2 million




Number of rounds up to CHF 10 m; n: 256

#SVCR19

#### Cantons


# **Zurich enters the Champions League**



ZurichCHF 515 million invested99 financing rounds43% of total investment

#### Cantons

# **Zurich enters the Champions League**



#### **Growth Zurich**

**ICT** 83%


**Fintech** > 400%

Biotech 114%

Healthcare IT 110%

#### Cantons

#### **Other winners**



# Zug: +143%

#### Basel-Stadt: +72%

# SVCR magazine

#### Interview, Articles, Analyses



- Interview Christian Wenger
- Investments of Swiss Pension Funds
- Exits
- Tokenisation

## Conclusion

- Startups: 30% more financing rounds
- Business Angels: growth and high level of professionalisation
- Funds: numerous projects
- Swiss funds: investments in larger rounds
- Pension funds: first significant investments
- Exits: some large and highly profitable examples

# Enjoy your reading...

- Print-Version
- PDF-Version with links to details Website: <u>www.startupticker.ch</u> under «Assets»

#SVCR19

• Contact persons:

Stefan Kyora, startupticker.ch: stefan.kyora@jnb.ch, Tel. 076 325 99 41 Thomas Heimann, SECA: thomas.heimann@seca.ch, Tel. 079 709 02 96



In cooperation with SECA – Swiss Private Equity & Corporate Finance Association